GuidelineESMO open2023
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer.
Guideline in ESMO open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Practice guideline for management of endometrial cancer in Thailand: a Thai Gynecologic Cancer Society consensus statement.Journal of gynecologic oncology · 2025Guideline
- Cancer-associated mutations in endometriosis reframe a benign disease through molecular oncology.Molecular oncology · 2026Review
- Review
- Associations between molecular subtypes and high-risk pathological factors in endometrial cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Consensus on Human Epidermal Growth Factor Receptor 2 Overexpression Testing in Pan-Tumor.Cancer innovation · 2026Article
- Hormone receptor status score is negatively correlated with adverse pathological features and serves as an independent prognostic factor in endometrial carcinoma.American journal of translational research · 2026Article
- Pattern of Lymph Node Metastasis and p53 Abnormal (p53abn) Expression in Preoperative Early-stage Endometrial Cancer: A 5-year Institutional Experience.Acta medica Philippina · 2026Article
- Prevalence of DNA Mismatch Repair Deficiencies in Multiple Solid Tumor Types in China.Journal of evidence-based medicine · 2025Article
- 'En bloc' peritoneal mesometrial resection (PMMR) and pelvic targeted compartmental lymphadenectomy (TCL) for management of patients with endometrial cancer - feasibility and safety study of a 'new kid on the block' in robotic surgery.World journal of surgical oncology · 2025Article
- Risk Stratification Prediction of Endometrial Cancer Using Microstructural Mapping Based on Time-Dependent Diffusion MRI.Cancer science · 2025Article
- Value of Routine Pelvic Examination in the Follow-Up of Patients Receiving Adjuvant Radiation Therapy for Endometrial Cancer: An Australian Tertiary-Centre Experience.Journal of medical imaging and radiation oncology · 2025Article
- Immunohistochemical Diversity of Endometrial Carcinoma and Their Implications in Prognosis: A Prospective Clinicopathological Study in a Tertiary Care Hospital of Eastern India.Journal of obstetrics and gynaecology of India · 2025Article
- A Machine Learning Approach to Build and Evaluate a Molecular Prognostic Model for Endometrial Cancer Based on Tumour Microenvironment.Journal of cellular and molecular medicine · 2025Article
- Methylation status of PAX1 and SF-1: implications for diagnosis and prognosis in endometrial cancer.American journal of cancer research · 2025Article
- Amide proton transfer-weighted imaging combined with multiple models diffusion-weighted imaging of endometrial cancer: correlations between multi-modal MRI parameters and HIF-1α expression.Frontiers in oncology · 2025Article
- Is fluorometric sentinel lymph node biopsy in endometrial cancer necessary?Frontiers in medicine · 2024Article
- High PLK3 levels are linked with less tumor invasion, lower FIGO stage and better prognosis of endometrial cancer.Biomarkers in medicine · 2024Article
- Machine learning models using multiparametric MRI for preoperative risk stratification in endometrial cancer.American journal of cancer research · 2024Article
- Correlation of several forms of folic acid with endometrial cancer: cross-sectional data from the National Health and Nutrition Examination Surveys (NHANES) 2011-2018.Journal of cancer research and clinical oncology · 2023Article
- Immune signatures of the POLE mutation in endometrial carcinomas: a systematic study based on TCGA data and clinical cohort validation.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with endometrial cancer was published in 2022. It was therefore decided, by both the ESMO and the Indian Society of Medical and Paediatric Oncology (ISMPO), to convene a virtual meeting in July 2022 to adapt the ESMO 2022 guidelines to take into account the variations in the management of endometrial cancer in Asia. These guidelines represent the consensus opinion of a panel of Asian experts representing the oncological societies of China (CSCO), India (ISMPO), Indonesia (ISHMO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO). Voting was based on scientific evidence and was conducted independently of the current treatment practices and treatment access constraints in the different Asian countries, which were discussed when appropriate. The aim of this guideline manuscript is to provide guidance for the optimisation and harmonisation of the management of patients with endometrial cancer across the different regions of Asia, drawing on the evidence provided by Western and Asian trials whilst respecting the variations in clinical presentation, diagnostic practices including molecular profiling and disparities in access to therapeutic options, including drug approvals and reimbursement strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.